|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:acquiredBy
|
gptkb:Celgene
$9 billion
|
|
gptkbp:acquisitionYear
|
2018
|
|
gptkbp:collaboratedWith
|
gptkb:Seattle_Children's_Research_Institute
gptkb:Memorial_Sloan_Kettering_Cancer_Center
gptkb:Celgene
gptkb:WuXi_AppTec
gptkb:Fred_Hutchinson_Cancer_Research_Center
|
|
gptkbp:focusesOn
|
gptkb:cancer
immunotherapy
|
|
gptkbp:foundedIn
|
2013
|
|
gptkbp:founder
|
gptkb:Hans_Bishop
gptkb:Lawrence_Corey
gptkb:Richard_Klausner
|
|
gptkbp:headquartersLocation
|
gptkb:Seattle,_Washington,_United_States
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Juno Therapeutics
|
|
gptkbp:industry
|
gptkb:biotechnology
|
|
gptkbp:notableProduct
|
gptkb:JCAR014
gptkb:JCAR015
gptkb:JCAR017
|
|
gptkbp:numberOfEmployees
|
over 300 (as of 2018)
|
|
gptkbp:parentCompany
|
gptkb:Bristol_Myers_Squibb
|
|
gptkbp:publiclyTraded
|
yes
|
|
gptkbp:specializesIn
|
gene therapy
TCR therapies
|
|
gptkbp:status
|
gptkb:subsidiary
|
|
gptkbp:stockExchange
|
gptkb:NASDAQ
|
|
gptkbp:stockSymbol
|
gptkb:JUNO
|
|
gptkbp:website
|
https://www.junotherapeutics.com/
|
|
gptkbp:bfsParent
|
gptkb:Stuart_Schreiber
|
|
gptkbp:bfsLayer
|
4
|